Figure 2.

Combination treatment with the fusion vaccine and PD1/TIM3/RGMb blockade prevents establishment of acute myeloid leukemia in vivo. C57BL/6J mice were retro-orbitally inoculated with 50x10³ syngeneic TIB-49 acute myeloid leukemia (AML) cells that were stably transduced with luciferase/mCherry. (A) Syngeneic dendritic cell (DC)/AML fusion cells were generated as described and evaluated for co-expression of tumor (mCherry) and DC (CD86) markers using flow cytometry. The mice (n=5 in each group) were then treated with either vaccine alone, anti-PD1/TIM3/RGMb (mAbs) or a combination of anti- PD1/TIM3/RGMb and the fusion vaccine. One group of mice was treated with appropriate isotype control as a negative control. (B) Bioluminescence imaging was performed serially starting on day 29 after inoculation (3 representative mice are shown). (C) The mice were followed for survival for 90 days. The results are shown in a Kaplan Meier curve.